Targeting ErbB3: The new RTK(id) on the prostate cancer block

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 131-149

  Jathal, Maitreyee K ^a   Chen, Liqun ^a,e   Mudryj, Maria ^b,d   Ghosh, Paramita M ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Departments of Microbiology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Castration resistance; EGFR; ErbB2; ErbB3; Erlotinib; HER2; HER3; Lapatinib; Prostate cancer; Trastuzumab

Indexed keywords

AMG 888; AMUVATINIB; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AZD 8931; CANERTINIB; CETUXIMAB; CL 1033; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; GEFITINIB; LAPATINIB; MM 121; PERTUZUMAB; PROTEIN TYROSINE KINASE; PROVENGE; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 79959923451     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/187152211795495643     Document Type: Review

References (137)

1. Adams, J. The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet, 1853, 1(1), 393-393.
2. Pisu, M.; Oliver, J. S.; Kim, Y. I.; Elder, K.; Martin, M.; Richardson L. C. Treatment for older prostate cancer patients: disparities in a southern state. Med. Care, 2010, 48(10), 915-922.
3. Williams, H.; Powell, I. J. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol. Biol., 2009, 472, 439-453.
4. Galvin, D. J.; Eastham, J. A. Critical appraisal of outcomes following open radical prostatectomy. Curr. Opin. Urol., 2009, 19(3), 297-302.
5. Marcus, D. M.; Jani, A. B.; Godette, K.; Rossi, P. J. A review of lowdose- rate prostate brachytherapy--techniques and outcomes. J. Natl. Med. Assoc., 2010, 102(6), 500-510.
6. Huggins, C.; Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin., 1972, 22(4), 232-240.
7. Diaz, M.; Patterson, S. G. Management of androgen-independent prostate cancer. Cancer Control, 2004, 11(6), 364-373.
8. Labrie, F.; Belanger, A.; Cusan, L.; Labrie, C.; Simard, J.; Luu- The, V.; Diamond, P.; Gomez, J.-L.; Candas, B. History of LHRH agonist and combination therapy in prostate cancer. Endocr. Relat. Cancer, 1996, 3(3), 243-278.
9. Thompson, I. M. Flare associated with LHRH-agonist therapy. Rev. Urol., 2001, 3(Suppl. 3), S10-14.
10. Akaza, H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci., 2011, 102(1), 51-56.
11. Petrylak, D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int., 2005, 96(Suppl. 2), 41-46.
12. Higano, C. S.; Small, E. J.; Schellhammer, P.; Yasothan, U.; Gubernick, S.; Kirkpatrick, P.; Kantoff, P. W. Sipuleucel-T. Nat. Rev. Drug Discov., 2010, 9(7), 513-514.
13. Berges, R. R.; Vukanovic, J.; Epstein, J. I.; CarMichel, M.; Cisek, L.; Johnson, D. E.; Veltri, R. W.; Walsh, P. C.; Isaacs, J. T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res., 1995, 1(5), 473-480.
14. Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate, 1984, 5(5), 545-557.
15. Armas, O. A.; Aprikian, A. G.; Melamed, J.; Cordon-Cardo, C.; Cohen, D. W.; Erlandson, R.; Fair, W. R.; Reuter, V. E. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am. J. Surg. Pathol., 1994. 18(10), 979-991.
16. Matsushima, H., Goto, T.; Hosaka, Y.; Kitamura, T.; Kawabe, K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer, 1999, 85(8), 1822-1827.
17. Reuter, V. E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology, 1997, 49(3A Suppl), 16-22.
18. Westin, P.; Stattin, P.; Damber, J. E.; Bergh, A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol., 1995, 146(6), 1368-1375.
19. Murphy, W. M.; Soloway, M. S.; Barrows, G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer, 1991, 68(4), 821-828.
20. Bladou, F.; Vessella, R. L.; Buhler, K. R.; Ellis, W. J.; True, L. D.; Lange, P. H. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int. J. Cancer, 1996, 67(6), 785-790.
21. van Weerden, W. M.; van Kreuningen, A.; Elissen, N. M.; Vermeij, M.; de Jong, F. H.; van Steenbrugge, G. J.; Schröder, F. H. Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate, 1993, 23(2), 149-164.
22. Brändström, A.; Westin, P.; Bergh, A.; Cajander, S.; Damber, J. E. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res., 1994, 54(13), 3594-3601.
23. Westin, P.; Bergh, A.; Damber, J. E. Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate, but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma. Prostate, 1993, 22(1), 65-74.
24. English, H. F.; Kyprianou, N.; Isaacs, J. T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate, 1989, 15(3), 233-250.
25. Agus, D. B.; Golde, D. W.; Sgouros, G.; Ballangrud, A.; Cordon- Cardo, C.; Scher, H. I. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res., 1998, 58(14), 3009-3014.
26. Agus, D. B.; Cordon-Cardo, C.; Fox, W.; Drobnjak, M.; Koff, A.; Golde, D. W.; Scher, H. I. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst., 1999, 91(21), 1869-1876.
27. Edwards, J.; Bartlett, J. M. The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int., 2005, 95(9), 1320-1326.
28. Feldman, B. J.; Feldman, D. The development of androgenindependent prostate cancer. Nat. Rev. Cancer, 2001, 1(1), 34-45.
29. Ghosh, P. M.; Malik, S. N.; Bedolla, R. G.; Wang, Y.; Mikhailova, M.; Prihoda, T. J.; Troyer, D. A.; Kreisberg, J. I. Signal transduction pathways in androgen-dependent an.-independent prostate cancer cell proliferation. Endocr. Relat. Cancer, 2005, 12(1), 119-134.
30. Liao, X.; Tang, S.; Thrasher, J. B.; Griebling, T. L.; Li, B. Smallinterfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther., 2005, 4(4), 505-515.
31. Snoek, R.; Cheng, H.; Margiotti, K.; Wafa, L. A.; Wong, C. A.; Wong, E. C.; Fazli, L.; Nelson, C. C.; Gleave, M. E.; Rennie, P. S. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin. Cancer Res., 2009, 15(1), 39-47.
32. Cheng, H.; Snoek, R.; Ghaidi, F.; Cox, M. E.; Rennie, P. S. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res., 2006, 66(21), 10613-10620.
33. Wen, Y.; Hu, M. C.; Makino, K.; Spohn, B.; Bartholomeusz, G.; Yan, D. H.; Hung, M. C. HER-2/neu promotes androgenindependent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res., 2000, 60(24), 6841-6845.
34. Lukacs, R. U.; Lawson, D. A.; Xin, L.; Zong, Y.; Garraway, I.; Goldstein, A. S.; Memarzadeh, S.; Witte, O. N. Epithelial stem cells of the prostate and their role in cancer progression. Cold Spring Harb Symp. Quant. Biol., 2008, 73, 491-502.
35. Ghosh, P. M.; Malik, S.; Bedolla, R.; Kreisberg, J. I. Akt in prostate cancer: possible role in androgen-independence. Curr. Drug Metab., 2003, 4(6), 487-496.
36. Wang, Y.; Kreisberg, J. I.; Ghosh, P. M. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr. Cancer Drug Targets, 2007, 7(6), 591-604.
37. Cinar, B.; De Benedetti, A.; Freeman, M. R. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res., 2005, 65(7), 2547-2553.
38. Gross, M. E.; Jo, S.; Agus, D. B. Update on HER-kinase-directed therapy in prostate cancer. Clin. Adv. Hematol. Oncol., 2004, 2(1), 53-56, 64.
39. Lorenzo, G. D.; Bianco, R.; Tortora, G.; Ciardiello, F. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin. Prost Cancer, 2003, 2(1), 50-57.
40. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO. J., 2000, 19(13), 3159-3167.
41. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5(5), 341-354.
42. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2001, 2(2), 127-137.
43. Holbro, T.; Hynes, N. E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 195-217.
44. Riethmacher, D.; Sonnenberg-Riethmacher, E.; Brinkmann, V.; Yamaai, T.; Lewin, G. R.; Birchmeier, C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature, 1997, 389(6652), 725-730.
45. Crone, S. A.; Zhao, Y. Y.; Fan, L.; Gu, Y.; Minamisawa, S.; Liu, Y.; Peterson, K. L.; Chen, J.; Kahn, R.; Condorelli, G.; Ross, J. Jr.; Chien, K. R.; Lee, K. F. S ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med., 2002, 8(5), 459-465.
46. Ozcelik, C.; Erdmann, B.; Pilz, B.; Wettschureck, N.; Britsch, S.; Hubner, N.; Chien, K. R.; Birchmeier, C.; Garratt, A. N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA, 2002, 99(13), 8880-8885.
47. Stern, D. F. ErbBs in mammary development. Exp. Cell Res., 2003, 284(1), 89-98.
48. Ross, J. S.; Fletcher, J. A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells, 1998, 16(6), 413-428.
49. Lu, X.; Kang, Y. Epidermal growth factor signalling and bone metastasis. Br. J. Cancer, 2010, 102(3), 457-461.
50. Bronte, G.; Rizzo, S.; La Paglia, L.; Adamo, V.; Siragusa, S.; Ficorella, C.; Santini, D.; Bazan, V.; Colucci, G.; Gebbia, N.; Russo, A. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev., 2010, 36(Suppl. 3), S21-29.
51. Laurent-Puig, P.; Lievre, A.; Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin. Cancer Res., 2009, 15(4), 1133-1139.
52. Pignon, J.-C.; Koopmansch, B.; Nolens, G.; Delacroix, L.; Waltregny, D.; Winkler, R. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res., 2009, 69(7), 2941-2949.
53. Cai, C.; Portnoy, D. C.; Wang, H.; Jiang, X.; Chen, S.; Balk, S. P. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res., 2009, 69(12), 5202-5209.
54. Di Lorenzo, G.; Autorino, R.; De Laurentiis, M.; Cindolo, L.; D'Armiento, M.; Bianco, A. R.; De Placido, S. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori, 2004, 90(2), 163-170.
55. Craft, N.; Shostak, Y.; Carey, M.; Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 1999, 5(3), 280-285.
56. Mellinghoff, I. K.; Vivanco, I.; Kwon, A.; Tran, C.; Wongvipat, J.; Sawyers, C. L. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 2004, 6(5), 517-527.
57. Citri, A.; Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol., 2006. 7(7), 505-516.
58. Engelman, J. A.; Zejnullahu, K.; Gale, C.-M.; Lifshits, E.; Gonzales, A. J.; Shimamura, T.; Zhao, F.; Vincent, P. W.; Naumov, G. N.; Bradner, J. E.; Althaus, I. W.; Gandhi, L.; Shapiro, G. I.; Nelson, J. M.; Heymach, J. V.; Meyerson, M.; Wong, K.-K.; Jänne, P. A. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res., 2007, 67(24), 11924-11932.
59. Gonzales, A. J.; Hook, K. E.; Althaus, I. W.; Ellis, P. A.; Trachet, E.; Delaney, A. M.; Harvey, P. J.; Ellis, T. A.; Amato, D. M.; Nelson, J. M.; Fry, D. W.; Zhu, T.; Loi, C.-M.; Fakhoury, S. A.; Schlosser, K. M., Sexton, K. E.; Winters, R. T.; Reed, J. E.; Bridges, A. J.; Lettiere, D. J.; Baker, D. A.; Yang, J.; Lee, H. T.; Tecle, H.; Vincent, P. W. Antitumor activity and pharmacokinetic properties of PF- 00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther., 2008, 7(7), 1880-1889.
60. Grasso, A. W.; Wen, D.; Miller, C. M.; Rhim, J. S.; Pretlow, T. G.; Kung, H. J. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene, 1997, 15(22), 2705-2716.
61. Salzberg, M.; Rochlitz, C.; Morant, R.; Thalmann, G.; Pedrazzini, A.; Roggero, E.; Schonenberger, A.; Knuth A.; Borner, M. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie, 2007, 30(7), 355-360.
62. Gross, M.; Higano, C.; Pantuck, A.; Castellanos, O.; Green, E.; Nguyen, K.; Agus, D. B. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer, 2007, 7, 142.
63. Morris, M. J.; Reuter, V. E.; Kelly, W. K.; Slovin, S. F.; Kenneson, K.; Verbel, D.; Osman, I.; Scher, H. I. HER-2 profiling and targeting in prostate carcinoma. Cancer, 2002, 94(4), 980-986.
64. Ziada, A.; Barqawi, A.; Glode, L. M.; Varella-Garcia, M.; Crighton, F.; Majeski, S.; Rosenblum, M.; Kane, M.; Chen, L.; Crawford, E. D. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate, 2004, 60(4), 332-337.
65. Lara, P. N., Jr.; Chee, K. G.; Longmate, J.; Ruel, C.; Meyers, F. J.; Gray, C. R.; Edwards, R. G.; Gumerlock, P. H.; Twardowski, P.; Doroshow, J. H.; Gandara, D. R. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer, 2004, 100(10), 2125-2131.
66. Agus, D. B.; Akita, R. W.; Fox, W. D.; Lewis, G. D.; Higgins, B.; Pisacane, P. I.; Lofgren, J. A.; Tindell, C.; Evans, D. P.; Maiese, K.; Scher, H. I.; Sliwkowski, M. X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell, 2002, 2(2), 127-137.
67. de Bono, J. S.; Bellmunt, J.; Attard, G.; Droz, J. P.; Miller, K.; Flechon, A.; Sternberg, C.; Parker, C.; Zugmaier, G.; Hersberger- Gimenez, V.; Cockey, L.; Mason, M.; Graham, J. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone- Refractory prostate cancer. J. Clin. Oncol., 2007, 25(3), 257-262.
68. Sridhar, S. S.; Hotte, S. J.; Chin, J. L.; Hudes, G. R.; Gregg, R.; Trachtenberg, J.; Wang, L.; Tran-Thanh, D.; Pham, N.-A.; Tsao, M.-S.; Hedley, D.; Dancey, J. E.; Moore, M. J. A Multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am. J. Clin. Oncol., 2009, 1-1.
69. Sergina, N. V.; Rausch, M.; Wang, D.; Blair, J.; Hann, B.; Shokat, K. M.; Moasser, M. M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 2007, 445(7126), 437-441.
70. Lozano, J. J.; Soler, M.; Bermudo, R.; Abia, D.; Fernandez, P. L.; Thomson, T. M.; Ortiz, A. R. Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by factor analysis of microarray data. BMC Genomics, 2005, 6, 109-109.
71. Smith, B. L.; Chin, D.; Maltzman, W.; Crosby, K.; Hortobagyi, G. N.; Bacus, S. S. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br. J. Cancer, 2004, 91(6), 1190-1194.
72. Soler, M.; Mancini, F.; Meca-Cortés, O.; Sánchez-Cid, L.; Rubio, N.; López-Fernández, S.; Lozano, J. J.; Blanco, J.; Fernández, P. L.; Thomson, T. M. HER3 is required for the maintenance of neuregulin-dependent an.-independent attributes of malignant progression in prostate cancer cells. Int. J. Cancer, 2009, 125(11), 2565-2575.
73. Chen, L.; Siddiqui, S.; Bose, S.; Mooso, B.; Asuncion, A.; Bedolla, R. G.; Vinall, R.; Tepper, C. G.; Gandour-Edwards, R.; Shi, X.; Lu, X.-H.; Siddiqui, J.; Chinnaiyan, A. M.; Mehra, R.; deVere White, R.; Carraway, K. L.; Ghosh, P. M. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res., 2010, 70(14), 5994-6003.
74. Vakar-Lopez, F.; Cheng, C.-J.; Kim, J.; Shi, G. G.; Troncoso, P., Tu, S.-M.; Yu-Lee, L.-Y.; Lin, S.-H. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J. Pathol., 2004, 203(2), 688-695.
75. Chen, N.; Ye, X.-C.; Chu, K.; Navone, N. M.; Sage, E. H.; Yu-Lee, L.-Y.; Logothetis, C. J.; Lin, S.-H. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res., 2007, 67(14), 6544-6548.
76. Lee, H.; Akita, R. W.; Sliwkowski, M. X.; Maihle, N. J. A Naturally Occurring Secreted Human ErbB3 Receptor Isoform Inhibits Heregulin-stimulated Activation of ErbB2, ErbB3, and ErbB4. Cancer Res, 2001, 61(11), 4467-4473.
77. Koumakpayi, I. H.; Diallo, J.-S.; Le Page, C.; Lessard, L.; Gleave, M.; Bégin, L. R.; Mes-Masson, A.-M.; Saad, F. Expression and nuclear localization of ErbB3 in prostate cancer. Clin. Cancer Res., 2006. 12(9), 2730-2737.
78. Koumakpayi, I. H.; Diallo, J.-S.; Le Page, C.; Lessard, L.; Filali- Mouhim, A.; Bégin, L. R.; Mes-Masson, A.-M.; Saad, F. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int., 2007, 100(2), 303-309.
79. Cheng, C.-J.; Ye, X.-C.; Vakar-Lopez, F.; Kim, J.; Tu, S.-M.; Chen, D.-T.; Navone, N. M.; Yu-Lee, L.-Y.; Lin, S.-H.; Hu, M. C. T. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol. Cancer Res., 2007, 5(7), 675-684.
80. Tørring, N.; Jørgensen, P. E.; Sørensen, B. S.; Nexø, E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res., 2000, 20(1A), 91-95.
81. Kani, K.; Warren, C. M.; Kaddis, C. S.; Loo, J. A.; Landgraf, R. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin. J. Biol. Chem., 2005, 280(9), 8238-8247.
82. Kani, K.; Park, E.; Landgraf, R. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry, 2005, 44(48), 15842-15857.
83. Gregory, C. W.; Whang, Y. E.; McCall, W.; Fei, X.; Liu, Y.; Ponguta, L. A.; French, F. S.; Wilson, E. M.; Earp, H. S. Heregulininduced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin. Cancer Res., 2005, 11(5), 1704-1712.
84. Jones, J. T.; Akita, R. W. Sliwkowski, M. X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett., 1999, 447(2-3), 227-231.
85. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C.-M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Jänne, P. A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827), 1039-1043.
86. Ishizawar, R. C.; Miyake, T.; Parsons, S. J. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene, 2007, 26(24), 3503-3510.
87. Jiang, X.; Borgesi, R. A.; McKnight, N. C.; Kaur, R.; Carpenter, C. L.; Balk, S. P. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J. Biol. Chem., 2007, 282(45), 32689-32698.
88. Fu, A. K.; Fu, W. Y.; Cheung, J.; Tsim, K. W.; Ip, F. C.; Wang, J. H.; Ip, N. Y. Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat, Neurosci., 2001, 4(4), 374-381.
89. Kamalati, T.; Jolin, H. E.; Fry, M. J.; Crompton, M. R. Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene, 2000, 19(48), 5471-5476.
90. Hemi, R.; Paz, K.; Wertheim, N.; Karasik, A.; Zick, Y.; Kanety, H. Transactivation of ErbB2 and ErbB3 by tumor necrosis factoralpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins. J. Biol. Chem., 2002, 277(11), 8961-8969.
91. Walters, D. K.; French, J. D.; Arendt, B. K.; Jelinek, D. F. Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex. Oncogene, 2003, 22(23), 3598-3607.
92. Walters, D. K.; Jelinek, D. F. A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells. Oncogene, 2004, 23(6), 1197-1205.
93. Baselga, J.; Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer, 2009, 9(7), 463-475.
94. Yoo, J. Y.; Wang, X. W.; Rishi, A. K.; Lessor, T.; Xia, X. M.; Gustafson, T. A.; Hamburger, A. W. Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br. J. Cancer, 2000, 82(3), 683-690.
95. Lessor, T. J.; Hamburger, A. W. Regulation of the ErbB3 binding protein Ebp1 by protein kinase C. Mol. Cell. Endocrinol., 2001, 175(1-2), 185-191.
96. Liu, Z.; Ahn, J.-Y.; Liu, X.; Ye, K. Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc. Natl. Acad. Sci. USA, 2006, 103(29), 10917-10922.
97. Sithanandam, G.; Anderson, L. M. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther., 2008, 15(7), 413-448.
98. Zhang, Y.; Fondell, J. D.; Wang, Q.; Xia, X.; Cheng, A.; Lu, M. L.; Hamburger, A. W. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene, 2002, 21(36), 5609-5618.
99. Zhang, Y.; Hamburger, A. W. Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling. Br. J. Cancer, 2005, 92(1), 140-146.
100. Zhang, Y.; Linn, D.; Liu, Z.; Melamed, J.; Tavora, F.; Young, C. Y.; Burger, A. M.; Hamburger, A. W. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol. Cancer Ther., 2008, 7(10), 3176-3186.
101. Zhang, Y.; Wang, X.-W.; Jelovac, D.; Nakanishi, T.; Yu, M.-H.; Akinmade, D.; Goloubeva, O.; Ross, D. D.; Brodie, A.; Hamburger, A. W. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc. Natl. Acad. Sci. USA, 2005, 102(28), 9890-9895.
102. Gannon, P. O.; Koumakpayi, I. H.; Le Page, C.; Karakiewicz, P. I.; Mes-Masson, A.-M.; Saad, F. Ebp1 expression in benign and malignant prostate. Cancer Cell Int., 2008, 8, 18-18.
103. Diamonti, A. J.; Guy, P. M.; Ivanof, C.; Wong, K.; Sweeney, C.; Carraway, K. L. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc. Nat. Acad. Sci. USA, 2002, 99(5), 2866-2871.
104. Wu, X.; Yen, L.; Irwin, L.; Sweeney, C.; Carraway, K. L. Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. Mol. Cell. Biol., 2004, 24(17), 7748-7757.
105. Yen, L.; Cao, Z.; Wu, X.; Ingalla, E. R. Q.; Baron, C.; Young, L. J. T.; Gregg, J. P.; Cardiff, R. D.; Borowsky, A. D.; Sweeney, C.; Carraway, K. L. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res., 2006, 66(23), 11279-11286.
106. Hsieh, A. C.; Moasser, M. M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer, 2007, 97(4), 453-457.
107. Shi, F.; Telesco, S. E.; Liu, Y.; Radhakrishnan, R.; Lemmon, M. A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA, 2010, 107(17), 7692-7697.
108. Schoeberl, B.; Faber, A. C.; Li, D.; Liang, M. C.; Crosby, K.; Onsum, M.; Burenkova, O.; Pace, E.; Walton, Z.; Nie, L.; Fulgham, A.; Song, Y.; Nielsen, U. B.; Engelman, J. A.; Wong, K. K. An ErbB3 antibody, MM-121, is active in cancers with liganddependent activation. Cancer Res., 2010, 70(6), 2485-2494.
109. van der Horst, E. H.; Murgia, M.; Treder, M.; Ullrich, A. Anti- HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int. J. Cancer, 2005, 115(4), 519-527.
110. Motoyama, A. B.; Hynes, N. E.; Lane, H. A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res., 2002, 62(11), 3151-3158.
111. Garrett, J.; Olivares, M.; Rinehart, C.; Dave, B.; Cook, R.; Chang, J.; Arteaga, C. Transcriptional and post-translational upregulation of HER3 (ErbB3) counteracts antitumor effect of HER2 tyrosine kinase inhibitors. Cancer Res., 2009, 69(24 Supplement), 63-63.
112. Huang, X.; Gao, L.; Wang, S.; McManaman, J. L.; Thor, A. D.; Yang, X.; Esteva, F. J.; Liu, B. Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin. Cancer Res., 2010, 70(3), 1204-1214.
113. Konecny, G.; Finn, R.; Venkatesan, N.; Rusnak, D.; Gilmer, T.; Berger, M.; Chen, J.; Slamon, D. J.; Pegram, M. The novel dual kinase inhibitor GW572016 is particularly active in HER2-positive and trastuzumab-conditioned breast cancer cells. Breast Cancer Res. Treat., 2003, 82, S171-S171.
114. Konecny, G. E.; Pegram, M. D.; Venkatesan, N.; Finn, R.; Yang, G.; Rahmeh, M.; Untch, M.; Rusnak, D. W.; Spehar, G.; Mullin, R. J.; Keith, B. R.; Gilmer, T. M.; Berger, M.; Podratz, K. C.; Slamon, D. J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res., 2006, 66(3), 1630-1639.
115. Normanno, N.; Campiglio, M.; De Luca, A.; Somenzi, G.; Maiello, M.; Ciardiello, F.; Gianni, L.; Salomon, D. S.; Menard, S. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol., 2002, 13(1), 65-72.
116. Scaltriti, M.; Verma, C.; Guzman, M.; Jimenez, J.; Parra, J. L.; Pedersen, K.; Smith, D. J.; Landolfi, S.; Ramony Cajal, S.; Arribas, J.; Baselga, J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 2009, 28(6), 803-814.
117. Ye, D.; Mendelsohn, J.; Fan, Z. Augmentation of a humanized anti- HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene, 1999, 18(3), 731-738.
118. Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H.; Sledge, G.; Koehler, M.; Ellis, C.; Casey, M.; Vukelja, S.; Bischoff, J.; Baselga, J.; O'Shaughnessy, J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2- positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol., 2010, 28(7), 1124-1130.
119. Slichenmyer, W. J.; Elliott, W. L.; Fry, D. W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol., 2001, 28(5 Suppl. 16), 80-85.
120. Trinks, C.; Djerf, E. A.; Hallbeck, A.-L.; Jönsson, J.-I.; Walz, T. M. The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U- 937) cells. Biochem. Biophys. Res. Commun., 2010, 393(1), 6-10.
121. Dewji, M. R. Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn? J. Chemother., 2004, (16 Suppl. 4), 44-48.
122. Qi, W.; Cooke, L. S.; Stejskal, A.; Riley, C.; Croce, K. D.; Saldanha, J. W.; Bearss, D.; Mahadevan, D. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer, 2009, 9, 142-142.
123. Hickinson, D. M.; Klinowska, T.; Speake, G.; Vincent, J.; Trigwell, C.; Anderton, J.; Beck, S.; Marshall, G.; Davenport, S.; Callis, R.; Mills, E.; Grosios, K.; Smith, P.; Barlaam, B.; Wilkinson, R. W.; Ogilvie, D. AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer. Clin Cancer Res., 2010. 16 (4), 1159-1169.
124. Turke, A. B.; Zejnullahu, K.; Wu, Y. L.; Song, Y.; Dias-Santagata, D.; Lifshits, E.; Toschi, L.; Rogers, A.; Mok, T.; Sequist, L.; Lindeman, N. I.; Murphy, C.; Akhavanfard, S.; Yeap, B. Y.; Xiao, Y.; Capelletti, M.; Iafrate, A. J.; Lee, C.; Christensen, J. G.; Engelman, J. A.; Janne, P. A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell, 2010, 17(1), 77-88.
125. Liu, Y.; Majumder, S.; McCall, W.; Sartor, C. I.; Mohler, J. L.; Gregory, C. W.; Earp, H. S.; Whang, Y. E. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res., 2005, 65(8), 3404-3409.
126. Ye, D.; Mendelsohn, J.; Fan, Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin. Cancer Res., 1999, 5(8), 2171-2177.
127. Festuccia, C.; Gravina, G. L.; Muzi, P.; Biordi, L.; Ronchi, P.; Martella, O.; Vicentini, C.; Bologna, M. Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. Oncol. Rep., 2007, 18(5), 1321-1327.
128. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer, 2010, 10(2), 130-137.
129. Eichhorn, P. J. A.; Gili, M.; Scaltriti, M.; Serra, V.; Guzman, M.; Nijkamp, W.; Beijersbergen, R. L.; Valero, V.; Seoane, J.; Bernards, R.; Baselga, J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res., 2008, 68(22), 9221-9230.
130. Fan, Q.-W.; Cheng, C. K.; Nicolaides, T. P.; Hackett, C. S.; Knight, Z. A.; Shokat, K. M.; Weiss, W. A. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res., 2007, 67(17), 7960-7965.
131. Junttila, T. T.; Akita, R. W.; Parsons, K.; Fields, C.; Lewis Phillips, G. D.; Friedman, L. S.; Sampath, D.; Sliwkowski, M. X. Ligandindependent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell, 2009, 15(5), 429-440.
132. Posadas, E. M.; Gulley, J.; Arlen, P. M.; Trout, A.; Parnes, H. L.; Wright, J.; Lee, M. J.; Chung, E. J.; Trepel, J. B.; Sparreboom, A.; Chen, C.; Jones, E.; Steinberg, S. M.; Daniels, A.; Figg, W. D.; Dahut, W. L. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol. Ther., 2005, 4(10), 1133-1137.
133. Chee, K. G.; Longmate, J.; Quinn, D. I.; Chatta, G.; Pinski, J.; Twardowski, P.; Pan, C. X.; Cambio, A.; Evans, C. P.; Gandara, D. R.; Lara, P. N. Jr. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin. Genitourin. Cancer, 2007, 5(7), 433-437.
134. Robinson, D.; He, F.; Pretlow, T.; Kung, H. J. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA, 1996, 93(12), 5958-5962.
135. Vidal, G. A.; Clark, D. E.; Marrero, L.; Jones, F. E. A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene, 2007, 26(3), 462-466.
136. Williams, E. E.; Trout, L. J.; Gallo, R. M.; Pitfield, S. E.; Bryant, I.; Penington, D. J.; Riese, D. J. 2nd. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett., 2003, 192(1), 67-74.
137. Lin, S.-H.; Lee, Y.-C.; Choueiri, M. B.; Wen, S.; Mathew, P.; Ye, X.; Do, K.-A.; Navone, N. M.; Kim, J.; Tu, S.-M.; Yu-Lee, L.-Y.; Logothetis, C. J. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin. Cancer Res., 2008, 14(12), 3729-3736.